• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    3/28/24 12:31:26 PM ET
    $AVTX
    $BDRX
    $KOD
    $MESO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    Gainers

    • Avalo Therapeutics (NASDAQ:AVTX) stock rose 363.1% to $22.0 during Thursday's regular session. The company's market cap stands at $17.6 million.
    • Xilio Therapeutics (NASDAQ:XLO) stock rose 133.95% to $1.5. The company's market cap stands at $41.1 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 71.82% to $1.48. The market value of their outstanding shares is at $6.2 million.
    • Mesoblast (NASDAQ:MESO) stock increased by 44.41% to $5.04. The company's market cap stands at $511.4 million.
    • Ontrak (NASDAQ:OTRK) stock increased by 37.66% to $0.82. The company's market cap stands at $22.5 million.
    • Nexalin Technology (NASDAQ:NXL) stock moved upwards by 35.85% to $1.06. The company's market cap stands at $7.7 million.

    Losers

    • Tonix Pharmaceuticals (NASDAQ:TNXP) shares decreased by 35.8% to $0.21 during Thursday's regular session. The market value of their outstanding shares is at $12.3 million.
    • Kodiak Sciences (NASDAQ:KOD) stock fell 18.6% to $6.07. The market value of their outstanding shares is at $318.2 million. As per the press release, Q4 earnings came out today.
    • NuCana (NASDAQ:NCNA) shares decreased by 15.19% to $0.26. The company's market cap stands at $13.7 million.
    • Oncology Institute (NASDAQ:TOI) shares fell 13.59% to $1.59. The company's market cap stands at $117.2 million. As per the news, the Q4 earnings report came out yesterday.
    • Vincerx Pharma (NASDAQ:VINC) stock fell 13.21% to $5.26. The market value of their outstanding shares is at $112.4 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) stock decreased by 13.13% to $0.71. The market value of their outstanding shares is at $7.8 million. As per the press release, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $BDRX
    $KOD
    $MESO

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    Kodiak Sciences Inc
    $KOD
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    Kodiak Sciences Inc
    $KOD
    10/24/2025$24.00Neutral → Overweight
    Analyst
    Kodiak Sciences Inc
    $KOD
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    Kodiak Sciences Inc
    $KOD
    9/22/2025$15.00Buy
    Jefferies
    More analyst ratings

    $AVTX
    $BDRX
    $KOD
    $MESO
    SEC Filings

    View All

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/10/26 8:05:34 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    3/9/26 8:00:33 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    3/6/26 10:05:20 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Taylor Carolyn E. bought $15,061 worth of shares (418 units at $36.03) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/21/25 5:22:56 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Treco James bought $9,000 worth of shares (250 units at $36.00) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/20/25 4:15:15 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Legal Officer Varki Paul

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:24:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

    Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and significant improvements in all key secondary endpoints as compared to placebo In pooled post hoc analysis of the pivotal RELIEF and RELISIENT studies, TONMYA showed favorable benefit-risk profile using number needed to treat, number needed to harm, and likelihood to be helped or harmed BERKELEY HEIGHTS, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, com

    3/10/26 8:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

    TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well tolerated BERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on TONMYATM (cyclobenzaprine HCl sublingual tablets), at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, in Salt Lake City, Utah. "The data presented at the AAPM PainConnect Annual Meeting support

    3/9/26 4:30:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $KOD
    $MESO
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13758646. The

    2/26/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

    CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended September 30, 2025 and updated its full year 2025 guidance. Recent Operational Highlights Fee-for-service revenue growth of 13% over Q3 2024, driven by continued organic growth performance in Florida and Oregon.Retail Pharmacy and Dispensary set fill records, contributing $75.9 million in revenue and $12.8 million in gross profit in Q3. Signed several new in-network MSO providers in the Florida market and opened our new TOI pharmacy

    11/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilas

    11/7/25 9:05:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care